Clinical Trial: Study on the Regulatory Mechanism of Uveitis Recurrence Mediated by Macrophage P2X7 Receptor via Gut Dysbiosis and Blood–Retinal Barrier Breakdown (China)

Posted On: 2026-08-14

China, Aug. 14 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Study on the Regulatory Mechanism of Uveitis Recurrence Mediated by Macrophage P2X7 Receptor via Gut Dysbiosis and Blood–Retinal Barrier Breakdown'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130054

Registration Time: 2026/08/13

Type: Observational study

Primary Sponsor: Peking University People's Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336315

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Study on the Regulatory Mechanism of Uveitis Recurrence Mediated by Macrophage P2X7 Receptor via Gut Dysbiosis and Blood–Retinal Barrier Breakdown (China)